【摘要】 结核病是由结核分枝杆菌感染引起的一种慢性传染病，可侵害人体的各种器官，以肺结核多见，是世界范围内导致死亡的主要原因之一。伴随着抗生素滥用和抗结核药物的不规范使用等问题，耐药肺结核不断出现，而耐药结核治疗的方案复杂、用药疗程长、药物不良反应多等问题，使临床工作面临严峻挑战。因此，临床上迫切需要对结核分枝杆菌感染，尤其是耐药菌株感染有效的新药。本文首先对已上市药物的有效性和安全性数据进行描述。其次结合药物主要作用靶点（结核分枝杆菌的细胞壁、蛋白质合成、能量代谢和DNA合成等）对当前临床研究阶段的新药进行详细阐述。更多还原

【Abstract】 Tuberculosis is a chronic infectious disease caused by mycobacterium tuberculosis infection, which can invade various organs of the human body. Pulmonary tuberculosis is the most common disease and is one of the main causes of death worldwide. With the abuse of antibiotics and non-standardized use of anti-tuberculosis drugs, drugresistant tuberculosis continues to emerge, and the treatment regimens for drug-resistant tuberculosis are complex, with the problems of long medication courses and many adverse drug reactions, etc., which brings great challenge to the clinical work. Therefore, there is an urgent clinical need for new drugs that are effective against mycobacterium tuberculosis infections, especially infections caused by drug-resistant strains. This article first describes the effectiveness and safety data of marketed drugs, and then elaborates the new drugs that are currently in the clinical research stage based on the main effect targets of the drugs(the cell wall of mycobacterium tuberculosis, protein synthesis, energy metabolism,DNA synthesis, etc.).更多还原